SS Innovations posts updated October 2026 presentation detailing growth, regulatory timelines and $42.5M 2025 revenue

SS Innovations (SSII) reported $42.5M revenue for 2025, up from $20.6M in 2024, with a 46.0% gross margin. The company also highlighted rapid adoption with 244 systems installed and 14,503 cumulative surgeries. Regulatory milestones include EU CE anticipated in Q4 2026 and US FDA market clearance in Q1 2027.

Original reporting

tradingview.com

Published Oct 5, 2026, 12:03 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 5, 2026, 12:08 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

SS Innovations posts updated October 2026 presentation detailing growth, regulatory timelines and $42.5M 2025 revenue — source image — Source · tradingview.com

Decision brief

The 30-second read

$SSIIBullishMed

Why it matters

The disclosed 2025 revenue and regulatory timeline could re‑price the stock.

Market read

First disclosure of 2025 revenue and FDA timeline provides actionable insight for traders.

What to watch

Potential supply chain constraints and competition from larger med‑tech firms.

Relevance 6/10Novelty 7/10Timing: immediate (Oct 5 2026 release)

Background

SS Innovations International, Inc. (SSII) filed an 8‑K with an updated investor presentation.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SSIIBullishHigh confidence

Context

Updated presentation disclosed 2025 revenue of $42.5M and FDA clearance target for Q1 2027.

Expected impact

likely upward pressure as investors price in higher revenue and near‑term FDA clearance.

Evidence & confidence

First‑time disclosure of 2025 revenue and clear CE/FDA milestones provides fresh material for valuation.

Market effects

Sector

Positive signal for med‑tech devices and surgical robotics sector.

Regional

May boost US biotech/medical device investors.

Global

Limited to niche market; no broad macro effect.

Counterpoint

What could challenge this read

Revenue growth may be overstated; FDA clearance risk remains high.

Key entities

company
SS Innovations International, Inc.
Medical device maker reporting updated guidance.

Read at source ← All news

$WWBHighAI 8/10

Healthcare Stocks In Focus: WWB Surges 40%, LFMD Gains 30%, SSII Rises 20%, TNDM Advances 14%

Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.

rttnews.comNov 13

$SSIIMedAI 8/10

SS Innovations Responds To FDA Request For Additional Information On SSi Mantra Robotic System

SS Innovations International (SSII) responded to the FDA's request for additional data on its SSi Mantra surgical robotic system, submitting final study results on October 5, 2026. The FDA review is expected to conclude in Q1 2027. SSII's stock is currently trading at $2.47, down 3.10%.

rttnews.comOct 13

$SSIIMed

SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra

SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra FORT LAUDERDALE, Fla. – October 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII) , a

SEC EDGAR 8-KOct 13

$SSIIMedAI 8/10

A surgical robot sent final study data to the FDA. SS Innovations expects review to finish in early 2027.

SS Innovations (NASDAQ: SSII) submitted final study data to the FDA for its SSi Mantra surgical robotic system. The company expects the FDA to complete its review by early 2027. The submission includes data from expanded clinical and bridging studies, aiming to demonstrate safety and efficacy for U.S. market approval.

stocktitan.netOct 13

$SSIIMed

SS Innovations Reports Second Quarter 2026 Financial Results

SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SS Innovations Reports Second Quarter 2026 Financial Results Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales FORT LAUDERDALE, FLA – August 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq:

SEC EDGAR 8-KAug 13

$SSIILow

SS Innovations Announces Completion of World’s Longest-Distance Robotic Telesurgery

SS Innovations International (Nasdaq: SSII) said it completed a robot-assisted cardiac telesurgery between Georgetown, Guyana and Indore, India using its SSi Mantra system, covering about 12,500 miles (20,000 km) of fiber distance. The company said 22 cardiac telesurgeries have been done with SSi Mantra, and 173 telesurgeries globally; Guyana GA-FDD approved the system in May 2026.

manilatimes.netJun 4